30 September 2019

 

Sparrow Pharmaceuticals Selected for Podium Presentation at Oregon Bio 2019

 

Sparrow Pharmaceuticals, a clinical stage company that is developing next-generation corticosteroids, is honored to have been invited to present at Oregon Bio 2019: Innovating and Scaling our Region’s Growth on 29 October at World Trade Center Two in Portland. Sparrow CEO David Katz, Ph.D., said, “I’m glad to have the opportunity to share Sparrow’s story with the Oregon Bio community that we’ve only recently joined, and to get to know more of the colleagues who share my goal to build a vibrant biotechnology ecosystem in Oregon.” Event registration is available via https://www.oregonbio.org/events/

 

16 September 2019

 

Sparrow Pharmaceuticals Receives Favorable FDA Feedback

 

Sparrow Pharmaceuticals, a clinical stage company that is developing next-generation corticosteroids, welcomes the favorable review from the U.S. Food and Drug Administration of the Company's next planned clinical trial for its lead proprietary new chemical entity SPI-62. The trial will assess how well SPI-62, administered in tablet form, blocks acute adverse effects of high-dose oral corticosteroid administration. Sparrow expects to complete the trial in 2020.

 

5 September 2019

 

Sparrow Pharmaceuticals Passes $1M Capital Milestone

 

Sparrow Pharmaceuticals, a clinical stage company that is developing next-generation corticosteroids, has now attracted over $1 million of new capital in the year since the Company licensed its proprietary new chemical entities SPI-62 and SPI-09 from Astellas Pharma. Sparrow continues to seek additional capital to advance development of oral, ocular, and topical next-generation corticosteroids. Interested investors can request non-confidential Company materials from Sparrow CEO David Katz, Ph.D. david@sparrowpharma.com

 

26 August 2019

 

Sparrow Pharmaceuticals Selected as 2019 Tom Holce Entrepreneurship Award Semifinalist by Oregon Entrepreneurs Network

 

Sparrow Pharmaceuticals, a clinical stage company that is developing next-generation corticosteroids, is honored to be selected as a semifinalist for OEN’s prestigious Tom Holce entrepreneurship award. According to OEN Interim Executive Director Jim Coonan, “We had a large number of company nominations this year, and it was a significant achievement to be selected as a semifinalist out of this quality group.” Sparrow CEO David Katz, Ph.D. said, “It’s great that the Oregon entrepreneurial community recognizes Sparrow’s potential so quickly after the Company moved to Portland. I look forward to the award dinner and to give back as I’m able to the local innovation ecosystem.” The Tom Holce award dinner will take place on 29 October at the Oregon Convention Center. Tickets are available via https://www.oen.org/

 

15 August 2019

 

Sparrow Pharmaceuticals Files PCT Patent Application

 

Sparrow Pharmaceuticals, a clinical stage company that is developing next-generation corticosteroids, is pleased to announce that it has converted a US provisional patent application to PCT status. This filing is an important step in Sparrow’s strategy to extend US market exclusivity for products based on its lead proprietary new chemical entity SPI-62 beyond 2036, and similarly extend market exclusivity in other jurisdictions. Sparrow will continue to work closely with patent counsel at Global Patent Group to create additional intellectual property protection for both SPI-62 and its other proprietary asset SPI-09.

 

29 July 2019

 

Sparrow Pharmaceuticals Announces Grant of the 51st Patent for SPI-62

 

Sparrow Pharmaceuticals, a clinical stage company that is developing next-generation corticosteroids, has been granted, by Brazil, of the 51st composition of matter patent covering its lead proprietary new chemical entity SPI-62. Every SPI-62 patent for which Sparrow’s licensor Astellas Pharma had applied has now been granted. The corresponding US patent can potentially provide US market exclusivity through 2036, and varying market exclusivity in other jurisdictions (including all 22 European Patent Office member states, Japan, and China) depending on local law. A tablet formulation of SPI-62 is ready to start Phase 2 clinical trials as the basis for next-generation oral corticosteroid products.

 

24 June 2019

 

Sparrow Pharmaceuticals Announces Grant of Its 100th Patent

 

Sparrow Pharmaceuticals, a clinical stage company that is developing next-generation corticosteroids, has been granted of the 100th composition of matter patent covering its proprietary new chemical entities SPI-62 and SPI-09. Sparrow’s lead product, an oral formulation of SPI-62, is ready to start Phase 2 clinical trials and has potential to be the first medication that combines safety, efficacy, convenience, and cost-effectiveness for the approximately two million US patients who today rely on long-term therapy with current generation oral corticosteroids to control autoimmune diseases, blood cancers, and transplanted organ rejection.

 

9 June 2019

 

Sparrow Pharmaceuticals to Present at Keiretsu Forum Northern California

 

Sparrow Pharmaceuticals, a clinical stage company that is developing next-generation corticosteroids, has been invited to present for the Keiretsu Forum Northern California region. CEO David Katz, Ph.D., will be in San Francisco on 26 June, East Bay on 27 June, and Silicon Valley on 28 June. For times and locations of, and to be invited to attend, the road show contact Mary Blackburn mblackburn@keiretsuforum.com (415) 573-0751.

 

10 May 2019

 

Sparrow Pharmaceuticals Completes Keiretsu Forum Due Diligence

 

Sparrow Pharmaceuticals, a clinical stage company that is developing next-generation corticosteroids, is pleased to announce completion of Keiretsu Forum Northwest due diligence on the Company. Interested investors can obtain a copy of the report from CEO David Katz, Ph.D. david@sparrowpharma.com and also have an opportunity to meet Dr. Katz during the Keiretsu Forum Northwest road show 13-17 May. Times and locations of, and how to attend, the road show can be found at https://www.k4northwest.com/cpages/homepage

 

12 April 2019

Sparrow Pharmaceuticals Awarded Business Oregon Enhanced Phase 0 Grant

Sparrow Pharmaceuticals, a clinical stage company that is developing safe replacements for prednisone and other corticosteroids, has been awarded an Enhanced Phase 0 grant by Business Oregon. The funds will be used to file additional intellectual property and for development activities in support of Sparrow's most advanced asset, a Phase 2 clinical trial-ready tablet that will be administered with oral corticosteroids to block many of the latter drugs' side effects.

7 April 2019

Sparrow Pharmaceuticals to Present at Life Science Innovation Northwest

Sparrow Pharmaceuticals, a clinical stage company that is developing safe replacements for prednisone and other corticosteroids, has been selected as a podium presenter at Life Science Innovation Northwest. LSINW, the Pacific Northwest’s biggest annual life science conference, brings together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and feature some of the most compelling technology breakthroughs of our time. Sparrow's presentation will be at 4:30 pm on Wednesday 24 April 2019 in Room 608 of the Washington State Convention Center in Seattle WA. Sparrow's CEO, David Katz, Ph.D., will be available throughout the conference for investor meetings.

11 March 2019

Sparrow Pharmaceuticals Named Best Seed Stage Company of Cascadia Venture Forum

Sparrow Pharmaceuticals, a clinical stage company that is developing safe replacements for prednisone and other corticosteroids, was named Best Seed Stage Company of Cascadia Venture Forum. CVF showcases the highest quality, investor-worthy, health innovation start-ups from the Cascadia Innovation Corridor, connecting BC, WA and OR, and was part of BCTech Summit in Vancouver BC. Sparrow's CEO, David Katz, Ph.D., said, "It's an honor to be selected from a group of dynamic and promising Pacific Northwest early stage companies."

20 February 2019

Sparrow Pharmaceuticals to Present at Keiretsu Angel Capital Expo and Cascadia Venture Forum

Sparrow Pharmaceuticals, a clinical stage company that is developing safe replacements for prednisone and other corticosteroids, has been selected to participate in two prestigious Pacific Northwest investor events. 

 

Angel Capital Expo, the premier gathering of the angel capital community, brings together investors and entrepreneurs looking for funding and is is organized by Keiretsu Forum, the world’s largest angel investment network. Sparrow's presentation will be at 9:25 am on Friday 8 March 2019 in Building 33 on the Microsoft campus in Redmond WA. Sparrow's CEO, David Katz, Ph.D., and COO, Jeffrey Drajesk, will be available throughout the conference for investor meetings.

Cascadia Venture Forum showcases the highest quality, investor-worthy, health innovation start-ups from the Cascadia Innovation Corridor, connecting BC, WA and OR, and will be part of BCTech Summit in Vancouver BC. Sparrow will participate in the seed stage company pitch competition in the afternoon of Monday 11 March 2019 in the Vancouver Conference Center East. Sparrow's CEO, David Katz, Ph.D., will be available throughout the day for investor meetings.

2 January 2019

Sparrow Pharmaceuticals Relocates Headquarters to Portland Oregon

Sparrow Pharmaceuticals, a clinical stage company that is developing safe replacements for prednisone and other corticosteroids, has relocated its headquarters to the Oregon Bioscience Incubator in Portland OR. OBI is managed by the Oregon Translational Research and Development Institute which was initiated in 2007 with a mission to translate scientific research developed in the state of Oregon’s research laboratories into commercial ventures. Sparrow's CEO, David Katz, Ph.D., said, "Sparrow looks forward to the support of OTRADI in our efforts to develop safer corticosteroids. I personally am excited to interact with the other life sciences entrepreneurs in OBI."

12 November 2018

Sparrow Pharmaceuticals Gains Seed Commitment from Prevail Partners

Sparrow Pharmaceuticals, a clinical stage company that is developing safe replacements for prednisone and other corticosteroids, has received a commitment for seed round investment from Prevail Partners, a fund designed to take advantage of, at very favorable terms, the attractive returns possible in promising scientific advances in the fields of healthcare therapies, preventive treatments, medical devices and diagnostics. A uniquely favorable feature of the fund is that Prevail InfoWorks applies proprietary technologies to equip companies in which the fund invests, giving investors comfort that the trials have a high likelihood of success. Sparrow's CEO, David Katz, Ph.D., said, "Sparrow is thrilled to have Prevail Partners and Prevail InfoWorks as partners in our efforts to develop safer corticosteroids. The Prevail platform provides a tiny company like Sparrow clinical trial informatics comparable to the best of Big Pharma."

1 November 2018

Sparrow Pharmaceuticals Receives Seed Investment from Chicago ArchAngels

Sparrow Pharmaceuticals, a clinical stage company that is developing safe replacements for prednisone and other corticosteroids, has received seed round investment from Chicago ArchAngels, a preferred provider of risk capital for early stage and seed stage companies in the Midwest and around the country. Sparrow's CEO, David Katz, Ph.D., said, "The first external investment in a new company might be the most meaningful. Both Jeff and I are honored that Chicago ArchAngels has put their trust in us and demonstrated belief that we'll succeed to develop safer corticosteroids."

10 September 2018

Sparrow Pharmaceuticals to Open Convertible Note Seed Investment Opportunity

Sparrow Pharmaceuticals, a clinical stage company that is developing safe replacements for prednisone and other corticosteroids, announced that it seeks investment to support development of its most advanced asset, a Phase 2 clinical trial-ready tablet (SPI-62) that will be administered with oral corticosteroids to block many of the latter drugs' side effects. Proceeds of convertible notes will be used to conduct a clinical trial to assess how well SPI-62 blocks acute corticosteroid side effects, and other development activities. Sparrow's CEO, David Katz, Ph.D., said, "Millions of patients rely on long-term corticosteroid therapy to control autoimmune diseases, blood cancers, and transplanted organ rejection. But they do so at high risk of serious side effects such as diabetes, hypertension, obesity, fractures, skin and muscle atrophy, glaucoma, and sleep, mood, and cognitive deficits. Sparrow aims to develop a solution to those patients' dilemma - a potent corticosteroid product without many of the side effects."

15 August 2018

Sparrow Pharmaceuticals Announces License for Worldwide Exclusive Rights to Two Astellas Pharma Compounds

Sparrow Pharmaceuticals, Inc. (“Sparrow”), a privately held pharmaceutical company, announced today that Sparrow has entered into an exclusive licensing agreement with Astellas Pharma, Inc. (“Astellas”) for exclusive global rights, across all human and non-human uses, to develop and commercialize two compounds that were discovered and initially developed by Astellas. Financial details regarding the transaction are not disclosed.

 

Sparrow is focused on development of novel drug candidates for concomitant use with corticosteroids in the treatment of autoimmune, inflammatory, and other conditions. The licensed compounds have potential to mitigate several serious adverse effects caused by corticosteroids, while maintaining the efficacy of those agents.

 

The lead licensed compound was well tolerated in Phase 1 and Phase 2 clinical trials conducted by Astellas for a distinct use. Sparrow will initially pursue clinical development of the lead compound in an orally administered dosage form for concomitant use with corticosteroids in the treatment of polymyalgia rheumatica, the most common autoimmune disease of the elderly.

 

Pre-clinical study results for the second licensed compound demonstrate a similar favorable safety profile. In addition, either compound has properties that support development in ocular, topical or inhalation dosage forms as well, which are aligned with other routes of administration for corticosteroids.

 

“We’re excited by this opportunity to develop new treatment options that are effective, safe, cost effective, and convenient for patients with polymyalgia rheumatica and other diseases,” stated Dr. David Katz, the founder and chief executive officer of Sparrow. “We look forward to build upon the high-quality data generated by Astellas, and to advance the compounds for patients who can benefit from corticosteroid therapy but suffer from, or are concerned about, adverse effects.”

copyright (c) 2019 Sparrow Pharmaceuticals, Inc.